QRG Capital Management Inc. Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

QRG Capital Management Inc. lessened its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 1.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 316,768 shares of the company’s stock after selling 4,541 shares during the period. QRG Capital Management Inc.’s holdings in Takeda Pharmaceutical were worth $4,400,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TAK. Rise Advisors LLC acquired a new position in Takeda Pharmaceutical in the 1st quarter valued at $26,000. GAMMA Investing LLC purchased a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at $28,000. Principal Securities Inc. acquired a new position in Takeda Pharmaceutical in the fourth quarter valued at $28,000. First United Bank & Trust purchased a new position in Takeda Pharmaceutical during the fourth quarter worth about $29,000. Finally, Lindbrook Capital LLC grew its holdings in Takeda Pharmaceutical by 40.6% in the 4th quarter. Lindbrook Capital LLC now owns 4,065 shares of the company’s stock valued at $58,000 after buying an additional 1,174 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 2.9 %

TAK traded up $0.39 during midday trading on Wednesday, hitting $13.69. The company’s stock had a trading volume of 830,886 shares, compared to its average volume of 1,698,629. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $16.39. The firm has a 50-day moving average price of $13.16 and a two-hundred day moving average price of $13.83. The firm has a market cap of $43.33 billion, a P/E ratio of 24.18, a PEG ratio of 0.42 and a beta of 0.54. The company has a current ratio of 1.11, a quick ratio of 0.58 and a debt-to-equity ratio of 0.62.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.